TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03261115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No topical anesthesia
Description: Lack of use of topical anesthesia application prior to infiltration injection intra-orally
Study: NCT02922387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral support
Description: An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
Study: NCT01586988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMAGE Intervention
Description: Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
Study: NCT04141657

Intervention type: OTHER
Intervention: Pharmacogenetic test
Description: Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
Study: NCT02316509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0927
Description: GDC-0927 will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0927
Description: GDC-0927 will be administered as per schedule specified in the respective arm.
Study: NCT01088607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (UDCA)
Description: Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
Study: NCT02085031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal Roux-en-Y esophagojejunostomy
Description: During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Roux-en-Y esophagojejunostomy
Description: During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
Study: NCT04121078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin infusion.
Study: NCT03483129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation
Description: 15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
Study: NCT02480946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background therapy as described in the arm descriptions
Study: NCT02787239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Study: NCT00869778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: εPA-44
Description: subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: εPA-44
Description: subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
Study: NCT04476173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane - Penthrox
Description: ACS patients who received inhaled methoxyflurane as analgesic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: ACS patients who received intravenous morphine as analgesic treatment
Study: NCT00411580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03997045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise program
Description: Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
Study: NCT03196388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is \>95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy
Study: NCT01328444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 +GW642444 125/25
Description: 125mcg/ 25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 +GW642444 125/25
Description: 125mcg/ 25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 +GW642444 125/25
Description: 125mcg/ 25mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK 573719 +GW642444 125/25
Description: 125mcg/ 25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 + GW642444 62.5/25
Description: 62.5mcg/25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 + GW642444 62.5/25
Description: 62.5mcg/25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 + GW642444 62.5/25
Description: 62.5mcg/25mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 + GW642444 62.5/25
Description: 62.5mcg/25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 125
Description: 125mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK 573719 125
Description: 125mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 62.5
Description: 62.5mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK 573719 62.5
Description: 62.5mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plb
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plb
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plb
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plb
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plb
Description: Comparator
Study: NCT01741402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: The participants of the study trained 10 balance games during 14 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group was trained with balance exercises.
Study: NCT03171753

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire
Description: questionnarie will be performed before the application of headphone and after their removal.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnarie will be performed before the application of headphone and after their removal.
Study: NCT01438697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
Study: NCT03171753

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: laboratory test
Description: laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
Study: NCT01438697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Website
Description: Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
Study: NCT03479047

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assess diaphragmatic displacement (DD) using ultrasonography
Description: During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
Study: NCT02686294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug : HL151. 1T, once a day oral administration, for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug : HL151. 1T, once a day oral administration, for 4 days
Study: NCT03171753

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: laboratory test
Description: laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiac monitoring
Description: the cardiac monitoring will be performed through study period

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac monitoring
Description: the cardiac monitoring will be performed through study period

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin resistance
Description: the skin resistance monitoring will be performed through study period

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: skin resistance
Description: the skin resistance monitoring will be performed through study period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Listening prerecorded music through an individual headset for 30 min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No sound
Description: No sound through an individual headset for 30 min
Study: NCT03153384

Intervention type: PROCEDURE
Intervention: Blood Culture
Description: For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
Study: NCT01583829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: 3 times per week for 45 minutes for a total of 40 sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 3 times per week for 45 minutes for a total of 40 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: 6 30 minute calm breathing sessions over the course of 4 months
Study: NCT04497883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (400 mg)
Description: Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (400 mg)
Description: Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (200 mg)
Description: Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (800 mg)
Description: Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Study: NCT02567058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound exam
Description: Ultrasound exam with :~* 2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~* 1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~* 1 succession of 3 measures for group III

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPAQ questionnaire
Description: IPAQ questionnaire
Study: NCT04924439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
Study: NCT01104532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral tablet
Study: NCT02686294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
Study: NCT01384682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
Study: NCT01872338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy for Suicide
Description: Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: VA standard care for suicide prevention
Study: NCT01104532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral tablet
Study: NCT04067518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHP674
Description: SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m\^2: 2500 IU/m\^2 every 14 days if BSA \<0.6 m\^2: 82.5 IU/kg every 14 days
Study: NCT05891665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional traction of the impacted canine without corticotomy
Description: In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
Study: NCT01419132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 125-250 mg furosemide bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Furosemide
Description: 125-250 mf furosemide bid
Study: NCT03091504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Albuterol is a short acting inhaled bronchodilator
Study: NCT03157700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL media curriculum
Description: REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
Study: NCT00909207

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
Study: NCT00329056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
Study: NCT01277003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aculife Magnetic Wave Therapist
Description: two therapeutic points, each for 15 minutes
Study: NCT04481022

Intervention type: OTHER
Group type: OTHER
Intervention: proximal control exercises
Description: study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010).
Study: NCT01277003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: tow therapeutic points, each for 15 minutes
Study: NCT01675089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.